Suzhou, China

Hongqun Hu


 

Average Co-Inventor Count = 7.1

ph-index = 2

Forward Citations = 5(Granted Patents)


Location History:

  • Jiangsu, CN (2017)
  • Suzhou, CN (2022 - 2024)

Company Filing History:


Years Active: 2017-2024

where 'Filed Patents' based on already Granted Patents

5 patents (USPTO):

Title: Innovations of Hongqun Hu in Monoclonal Antibody Development

Introduction

Hongqun Hu is a prominent inventor based in Suzhou, China, known for his significant contributions to the field of biotechnology. He holds a total of five patents, focusing primarily on monoclonal antibodies that target specific antigens. His work has implications for the treatment of various tumors, showcasing his innovative approach to pharmaceutical development.

Latest Patents

One of Hu's latest patents is for a monoclonal antibody specifically binding to human and monkey CD38 antigens. This invention includes detailed amino acid sequences for the complementarity-determining regions of both the light and heavy chain variable regions of the antibody. The monoclonal antibody can be utilized in pharmaceutical compositions for treating tumors with positive CD38 expression, such as human myeloma and lymphoma.

Another notable patent involves a monoclonal antibody that binds to the human TIGIT antigen. This antibody has high affinity and antagonistically inhibits the binding of TIGIT to its ligand, CD155. The patent outlines the amino acid sequences for the complementarity-determining regions of the antibody, along with a humanization preparation method. This antibody can also be used in combination with other treatments, such as anti-PD-1 monoclonal antibodies, for tumor therapy.

Career Highlights

Hongqun Hu has worked with several companies in the biotechnology sector, including Acroimmune Biotech Co., Ltd. and Acroimmune Biopharma Co., Ltd. His experience in these organizations has allowed him to advance his research and development efforts in monoclonal antibody technology.

Collaborations

Hu has collaborated with notable colleagues, including Zui Chen and Qunmin Zhou. These partnerships have contributed to the successful development of his innovative antibody therapies.

Conclusion

Hongqun Hu's work in monoclonal antibody development represents a significant advancement in the field of biotechnology. His patents reflect a commitment to improving therapeutic options for patients with tumors, highlighting the importance of innovation in medical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…